Trial Profile

An open-label study to assess the effect of combination treatment with Avastin [bevacizumab] and Xeloda [capecitabine], plus pre-operative standard radiotherapy, on response rate in patients with locally advanced rectal cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil; Folinic acid
Indications Rectal cancer
Focus Therapeutic Use
Sponsors Roche

08 Sep 2011 Actual end date is April 2011 as reported by ClinicalTrials.gov.
08 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
19 Nov 2010 Planned End Date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com